Clémentine Jankowski

507 total citations
31 papers, 179 citations indexed

About

Clémentine Jankowski is a scholar working on Cancer Research, Oncology and Surgery. According to data from OpenAlex, Clémentine Jankowski has authored 31 papers receiving a total of 179 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cancer Research, 19 papers in Oncology and 8 papers in Surgery. Recurrent topics in Clémentine Jankowski's work include Breast Cancer Treatment Studies (22 papers), HER2/EGFR in Cancer Research (10 papers) and Breast Lesions and Carcinomas (8 papers). Clémentine Jankowski is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), HER2/EGFR in Cancer Research (10 papers) and Breast Lesions and Carcinomas (8 papers). Clémentine Jankowski collaborates with scholars based in France, Switzerland and United States. Clémentine Jankowski's co-authors include Charles Coutant, Laurent Arnould, Sylvain Ladoire, Françoise Beltjens, Isabelle Desmoulins, Céline Charon‐Barra, Catherine Loustalot, Aurélie Bertaut, Delphine Hudry and Alexandre Bricou and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Clémentine Jankowski

29 papers receiving 178 citations

Peers

Clémentine Jankowski
Bruna Salani Mota Brazil
Ingeborg J. H. Vriens Netherlands
Maggie Banys‐Paluchowski Germany
Rita Ceccherini Italy
Alicia Latham United States
H. Auvray France
Nicolas Pouget France
Ilaria Maugeri Italy
J F Rodier France
Latifa Fellah Belgium
Bruna Salani Mota Brazil
Clémentine Jankowski
Citations per year, relative to Clémentine Jankowski Clémentine Jankowski (= 1×) peers Bruna Salani Mota

Countries citing papers authored by Clémentine Jankowski

Since Specialization
Citations

This map shows the geographic impact of Clémentine Jankowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clémentine Jankowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clémentine Jankowski more than expected).

Fields of papers citing papers by Clémentine Jankowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clémentine Jankowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clémentine Jankowski. The network helps show where Clémentine Jankowski may publish in the future.

Co-authorship network of co-authors of Clémentine Jankowski

This figure shows the co-authorship network connecting the top 25 collaborators of Clémentine Jankowski. A scholar is included among the top collaborators of Clémentine Jankowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clémentine Jankowski. Clémentine Jankowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ladoire, Sylvain, Loïck Galland, Isabelle Desmoulins, et al.. (2025). Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib. npj Breast Cancer. 11(1). 10–10. 1 indexed citations
2.
3.
Bertaut, Aurélie, Sylvain Ladoire, Isabelle Desmoulins, et al.. (2024). HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity. Cancers. 16(11). 2009–2009. 1 indexed citations
4.
Classe, Jean‐Marc, L. Campion, Fabrice Lécuru, et al.. (2024). Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.. Journal of Clinical Oncology. 42(17_suppl). LBA5505–LBA5505. 8 indexed citations
5.
6.
Jankowski, Clémentine, et al.. (2024). Impact of breast surgical procedure on survival in BRCA mutated patients with invasive breast cancer: Mastectomy versus conservative treatment. Journal of Gynecology Obstetrics and Human Reproduction. 53(5). 102760–102760. 1 indexed citations
7.
Arnould, Laurent, Françoise Beltjens, Didier Mayeur, et al.. (2023). Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy. Breast Cancer. 30(6). 997–1007. 8 indexed citations
8.
Jankowski, Clémentine, Laura Vincent, Françoise Beltjens, et al.. (2023). Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact. Bulletin du Cancer. 110(6). 605–615. 5 indexed citations
9.
Ladoire, Sylvain, Clémentine Jankowski, Isabelle Desmoulins, et al.. (2023). HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study. Breast Cancer. 30(3). 343–353. 1 indexed citations
10.
Jankowski, Clémentine, et al.. (2023). Impact of the withdrawal of macrotextured implant on reconstruction practices. Bulletin du Cancer. 111(4). 338–346.
11.
Beltjens, Françoise, et al.. (2023). Abstract P5-01-11: Utility of 18F-FDG PET/CT for the prediction of pathologic complete response in axilla to neoadjuvant chemotherapy in breast cancer. Cancer Research. 83(5_Supplement). P5–1. 1 indexed citations
12.
Bertaut, Aurélie, Françoise Beltjens, Céline Charon‐Barra, et al.. (2023). Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers. British Journal of Cancer. 129(1). 122–134. 27 indexed citations
13.
Philip, Charles‐André, et al.. (2022). Quelles évolutions dans notre pratique de la mastectomie ? Analyse à partir de données de population dans un département français. Gynécologie Obstétrique Fertilité & Sénologie . 50(12). 770–776. 1 indexed citations
14.
Jankowski, Clémentine, et al.. (2022). Comparison of postoperative complications following conventional latissimus dorsi flap versus muscle-sparing latissimus dorsi flap breast reconstruction. Journal of Plastic Reconstructive & Aesthetic Surgery. 75(10). 3653–3663. 6 indexed citations
15.
Beltjens, Françoise, Aurélie Bertaut, Corentin Richard, et al.. (2021). ER−/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple‐negative breast cancer. International Journal of Cancer. 149(1). 200–213. 17 indexed citations
16.
Bertaut, Aurélie, Françoise Beltjens, Isabelle Desmoulins, et al.. (2021). Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort. Bulletin du Cancer. 109(3). 268–279. 3 indexed citations
17.
Arnould, Laurent, Françoise Beltjens, Isabelle Desmoulins, et al.. (2019). Stratégies en cas de positivité du ganglion sentinelle dans les cancers du sein. Bulletin du Cancer. 107(6). 672–685. 4 indexed citations
18.
Jankowski, Clémentine, Marion Cortet, Isabelle Desmoulins, et al.. (2016). Tumeurs localisées du sein triple négatives en 2016 : définitions et prise en charge. Gynécologie Obstétrique & Fertilité. 44(9). 492–504. 3 indexed citations
19.
Coutant, Charles, et al.. (2016). Peut-on proposer un prélèvement du ganglion sentinelle en cas de chimiothérapie néoadjuvante dans les cancers du sein et à quel moment ?. Gynécologie Obstétrique & Fertilité. 44(6). 345–349. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruna Salani Mota Breakdown of academic impact, for papers by Ingeborg J. H. Vriens Breakdown of academic impact, for papers by Maggie Banys‐Paluchowski Breakdown of academic impact, for papers by Rita Ceccherini Breakdown of academic impact, for papers by Alicia Latham Breakdown of academic impact, for papers by H. Auvray Breakdown of academic impact, for papers by Nicolas Pouget Breakdown of academic impact, for papers by Ilaria Maugeri Breakdown of academic impact, for papers by J F Rodier Breakdown of academic impact, for papers by Latifa Fellah
Rankless by CCL
2026